同步M1b-c期IV期非小细胞肺癌的肺切除术
本研究回顾性分析1995至2015年间23例接受转移灶治疗及根治性肺切除术的同步M1b-c期IV期非小细胞肺癌患者。中位年龄56岁,19例行肺叶切除,4行全肺切除。5年无进展生存率14.5%(95%CI 0%~30.6%),5年总生存率41.7%(95%CI 19.6%~63.8%)。部分患者获得较长生存,但最佳选择标准尚不明确。
要点
- 同步M1b-c期IV期NSCLC行根治性肺切除后5年总生存率41.7%。
- 5年无进展生存率仅14.5%,复发以远处转移为主(13例)。
- 部分患者可能为寡转移,但最佳筛选方法尚不明确。
核心结论
- 部分同步M1b-c期IV期NSCLC患者通过局部治疗转移灶及根治性肺切除可获得较长生存。
研究设计与样本
- 回顾性分析1995至2015年间23例连续接受转移灶治疗及根治性肺切除术的同步M1b-c期IV期NSCLC患者。
主要发现
- 17例腺癌,4例大细胞癌,1例大细胞神经内分泌癌,1例癌肉瘤。
- 13例无淋巴结转移,14例接受术前化疗,10例接受术后化疗。
- 转移部位:脑13例,骨3例,肾上腺及胸外淋巴结各2例,肝、小肠及皮下组织各1例。
- 19例行肺叶切除,4例行全肺切除;17例复发(局部3例,远处13例,两者兼有1例)。
关键数值与推荐
- 5年无进展生存率14.5%(95%CI 0%~30.6%)。
- 5年总生存率41.7%(95%CI 19.6%~63.8%)。
临床怎么用
- 对高度选择的同步M1b-c期IV期NSCLC患者,可考虑转移灶局部治疗联合根治性肺切除。
- 患者选择需多学科评估,目前尚无明确最佳筛选标准。
局限性
- 回顾性研究,样本量小(23例),可能存在选择偏倚。
- 部分寡转移患者可能被无意纳入,最佳患者选择方法不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We wanted to assess the efficacy of curative intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with synchronous M1b-distant metastases in a single organ or lesion. METHODS: Between 1995 and 2015, 23 consecutive synchronous M1b-cStage IV NSCLC patients who underwent any treatment for metastases and curative intent pulmonary resection were retrospectively analyzed. RESULTS: Sixteen patients were men and 7 were women, with a median age of 56 years (range: 41 to 76 years). There were 17 adenocarcinoma, 4 large-cell carcinoma, 1 large-cell neuroendocrine cancer, and 1 carcinosarcoma. Thirteen patients had no lymph node metastasis. Fourteen patients received preoperative chemotherapy, and 10 received postoperative chemotherapy. The metastatic sites were the brain in 13 patients; bone in 3 patients; adrenal glands and extrathoracic lymph nodes in 2 patients each; and the liver, small intestine, and subcutaneous tissue in 1 patient each. Nineteen patients underwent lobectomy, and the other 4 patients underwent pneumonectomy. Seventeen patients experienced recurrence as follows: local recurrence in 3 patients, distant recurrence in 13 patients, and both in 1 patient. The 5-year progression-free survival rates in the 23 patients was14.5% (95% confidence interval: 0% to 30.6%), and the 5-year overall survival rate was 41.7% (95% confidence interval: 19.6% to 63.8%). CONCLUSIONS: Some M1b-cStage IV NSCLC patients achieved longer survival than others with the same stage disease by using local treatment for distant metastases and curative intent pulmonary resection. Oligometastatic patients might have been inadvertently included in the present cohort. However, at present, the optimum method for patient selection remains unclear.
引用
- Yamaguchi M, Edagawa M, Suzuki Y, et al. Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients. Ann Thorac Surg. 2016. PMID: 27863731. doi:10.1016/j.athoracsur.2016.08.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。